Page last updated: 2024-10-16

adenine and Infections, Plasmodium

adenine has been researched along with Infections, Plasmodium in 11 studies

Research Excerpts

ExcerptRelevanceReference
"Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal administration (five times at 15 mg kg of body weight-1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]."7.69Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. ( Dorrestein, GM; Franssen, FF; Hermsen, RC; Nieuwenhuijs, H; Overdulve, JP; Smeijsters, LJ, 1996)
"Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal administration (five times at 15 mg kg of body weight-1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]."3.69Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. ( Dorrestein, GM; Franssen, FF; Hermsen, RC; Nieuwenhuijs, H; Overdulve, JP; Smeijsters, LJ, 1996)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19906 (54.55)18.7374
1990's2 (18.18)18.2507
2000's1 (9.09)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ondounda, M1
Tanon, A1
Ehui, E1
Ouattara, I1
Kassi, A1
Aba, YT1
Aoussi, EF1
Kakou, AR1
Eholié, SP1
Bissagnene, E1
Kadio, A1
Porter, KA1
Cole, SR1
Eron, JJ1
Zheng, Y1
Hughes, MD1
Lockman, S1
Poole, C1
Skinner-Adams, TS1
Hosseinipour, M1
Shaffer, D1
D'Amico, R1
Sawe, FK1
Siika, A1
Stringer, E1
Currier, JS1
Chipato, T1
Salata, R1
McCarthy, JS1
Meshnick, SR1
Kato, N1
Sakata, T1
Breton, G1
Le Roch, KG1
Nagle, A1
Andersen, C1
Bursulaya, B1
Henson, K1
Johnson, J1
Kumar, KA1
Marr, F1
Mason, D1
McNamara, C1
Plouffe, D1
Ramachandran, V1
Spooner, M1
Tuntland, T1
Zhou, Y1
Peters, EC1
Chatterjee, A1
Schultz, PG1
Ward, GE1
Gray, N1
Harper, J1
Winzeler, EA1
Tubaro, E1
Lotti, B1
Cavallo, G1
Croce, C1
Borelli, G1
Smeijsters, LJ1
Nieuwenhuijs, H2
Hermsen, RC1
Dorrestein, GM1
Franssen, FF2
Overdulve, JP2
de Vries, E1
Stam, JG1
Chavalitshewinkoon, P1
de Clercq, E1
van der Vliet, PC1
Jacobs, RL1
Miller, LH1
Koontz, LC1
Lukow, I1
Schmidt, G1
Walter, RD1
Königk, E1
Muto, T1
Ebisawa, I1
Mitsui, G1
Ilan, J2
Tokuyasu, K1
Büngener, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505]Phase 3745 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants Who Experienced HIV-related Disease Progression or Death

Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP6
NVP/LPV_r4
NoNVP/NVP19
NoNVP/LPV_r26

Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.

The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP15
NVP/LPV_r0
NoNVP/NVP35
NoNVP/LPV_r0

Number of Participants Who Experienced Virologic Failure or Died.

Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP32
NVP/LPV_r10
NoNVP/NVP42
NoNVP/LPV_r50

Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality

Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.

Interventionparticipants (Number)
NVP/NVP20
NoNVP/NVP51

CD4 Count Change From Randomization

Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.

,,,
Interventioncells/mm^3 (Median)
Week 48 CD4 count change from randomizationWeek 96 CD4 count change from randomization
NoNVP/LPV_r172256
NoNVP/NVP172223
NVP/LPV_r201278
NVP/NVP191291

Percent of Participants Who Experienced Virologic Failure or Died

Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
InterventionPercent of participants (Number)
week 48 percent of virologic failure or deathweek 96 percent of virologic failure or death
NoNVP/LPV_r1420
NoNVP/NVP1417
NVP/LPV_r412
NVP/NVP2331

Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month

Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
Interventionpercent of participants (Number)
week 48 percent of full adherence in past monthweek 96 percent of full adherence in past month
NoNVP/LPV_r8687
NoNVP/NVP9093
NVP/LPV_r8895
NVP/NVP8994

Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NVP/LPV_r6084NA
NVP/NVP121260

Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NoNVP/LPV_r1236132
NoNVP/NVP2436NA

Trials

1 trial available for adenine and Infections, Plasmodium

ArticleYear
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease

2012

Other Studies

10 other studies available for adenine and Infections, Plasmodium

ArticleYear
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:2

    Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d

2011
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
    Nature chemical biology, 2008, Volume: 4, Issue:6

    Topics: Adenine; Animals; Antimalarials; Cell Line; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; C

2008
Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism.
    Biochemical pharmacology, 1980, Jul-01, Volume: 29, Issue:13

    Topics: Adenine; Allopurinol; Animals; Carcinoma, Ehrlich Tumor; Liver; Malaria; Mice; Plasmodium berghei; S

1980
Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:7

    Topics: Adenine; Animals; Antimalarials; Delayed-Action Preparations; Malaria; Mice; Mice, Inbred BALB C; Or

1996
Inhibition of the growth of Plasmodium falciparum and Plasmodium berghei by the DNA polymerase inhibitor HPMPA.
    Molecular and biochemical parasitology, 1991, Volume: 47, Issue:1

    Topics: Adenine; Animals; Antiprotozoal Agents; Binding, Competitive; Cell Line; Deoxyadenine Nucleotides; E

1991
Labeling of sporozoites of Plasmodium berghei with tritiated purines.
    The Journal of parasitology, 1974, Volume: 60, Issue:2

    Topics: Adenine; Adenosine; Animals; Anopheles; Blood; Deoxyadenosines; Deoxyribonucleosides; Guanosine; Iso

1974
[Adenosine monophosphate salvage synthesis in Plasmodium chabaudi].
    Zeitschrift fur Tropenmedizin und Parasitologie, 1973, Volume: 24, Issue:4

    Topics: Adenine; Adenosine Monophosphate; Aminohydrolases; Animals; Carbon Radioisotopes; Clinical Enzyme Te

1973
Malaria in Laos. II. Peripheral leucocyte counts during long-term administration of combined folic inhibitors (pyrimethamine with sulformethoxine or sulfamonomethoxine).
    The Japanese journal of experimental medicine, 1971, Volume: 41, Issue:5

    Topics: Adenine; Administration, Oral; Aniline Compounds; Asian People; Drug Combinations; Folic Acid Antago

1971
Phosphorylation of D-Arabinosyl adenine by Plasmodium berghei and its partial protection of mice against malaria.
    Nature, 1970, Dec-26, Volume: 228, Issue:5278

    Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Arabinose; Chr

1970
[Incorporation of exogenous adenosine and hypoxanthine in the nucleic acids of malaria parasites (Plasmodium berghei and Plasmodium vinckei)].
    Zeitschrift fur Parasitenkunde (Berlin, Germany), 1968, Volume: 31, Issue:1

    Topics: Adenine; Erythrocytes; Hypoxanthines; Malaria; Nucleosides; Plasmodium; Tritium

1968